Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NMTR
- Price
- -
- Stock movement up
- +0.00 (2.05%)
- Company name
- 9 Meters Biopharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology & Medical Research
- Market cap
- 287.75K
- Ent value
- 8.96M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- 6030.15%
- Div growth
- -17.81%
- Growth years
- 1
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -53.87%
- 1 year return
- -99.53%
- 3 year return
- -88.91%
- 5 year return
- -82.97%
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
Dividend yield - 5y
Loading...
Dividend yield data
| Dividend per share | 1.20 |
| Dividend yield | 6030.15% |
| Payout frequency | Quarterly |
| Maximum yield | 10909.09% |
| Average yield | 7766.26% |
| Minimum yield | 1662.05% |
| Discount to avg yield | -28.79% |
| Upside potential | -22.35% |
| Yield as % of max yield | 55.28% |
Yield distribution (inverse percentile) - 5y
Loading...
Yield distribution data
| Dividend yield | 6030.15% |
| Current yield distribution | 80.00% |
| Yield at 100% (Min) | 1662.05% |
| Yield at 90% | 4994.54% |
| Yield at 80% | 6129.11% |
| Yield at 50% (Median) | 8163.27% |
| Yield at 20% | 9663.47% |
| Yield at 10% | 10000.00% |
| Yield at 0% (Max) | 10909.09% |
Dividend per share
Loading...
Dividend per share data
| Years of growth | 1 years |
| CCC status | - |
| Dividend per share | 1.20 |
| Payout frequency | Quarterly |
| Ex-div date | 28 Jun 2024 |
| EPS (TTM) | -3.66 |
| EPS (1y forward) | -1.23 |
| EPS growth (5y) | -53.87% |
| EPS growth (5y forward) | - |
Dividend growth
Loading...
Please create a free account or log in to access this chart
Dividend growth data
| NMTR | S&P500 | |
| DGR MR | -33.33% | -13.74% |
| DGR TTM | -25.57% | 6.60% |
| DGR 3 years | 87.62% | 5.24% |
| DGR 5 years | -17.81% | 5.40% |
| DGR 10 years | - | 7.07% |
| DGR 15 years | - | 6.12% |
| Time since last change announced | 488 days |
| EPS growth (5y) | -53.87% |
| EPS growth (5y forward) | - |
Payout ratio
Loading...
Please create a free account or log in to access this chart
Payout ratio data
| EPS coverage | FCF coverage | |
| TTM | - | - |
| Average | - | - |
| Forward | -97.56% | - |
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 14.46M |
| EPS (TTM) | -3.66 |
| FCF per share (TTM) | -2.74 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -43.44M |
| Net income (TTM) | -49.80M |
| EPS (TTM) | -3.66 |
| EPS (1y forward) | -1.23 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 6.94M |
| Net receivables | 0.00 |
| Total current assets | 9.20M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 9.31M |
| Accounts payable | 4.23M |
| Short/Current long term debt | 5.17M |
| Total current liabilities | 15.58M |
| Total liabilities | 15.61M |
| Shareholder's equity | -6.30M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -37.24M |
| Capital expenditures (TTM) | 2.84K |
| Free cash flow (TTM) | -37.25M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -534.74% |
| Return on Invested Capital | 4276.80% |
| Cash Return on Invested Capital | 3198.73% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| NMTR | S&P500 | |
| Current price drop from All-time high | -100.00% | -10.85% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 13 Sep 2023 | 9 Mar 2009 |
| Avg drop from high | -88.16% | -11.07% |
| Avg time to new high | 363 days | 12 days |
| Max time to new high | 1381 days | 1805 days |
COMPANY DETAILS
Marketcap
287.75K
Marketcap category
Small-cap
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.
Employees
10
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner